Join the #FierceMadness!
Pick your favorite drug names in this year's tournament challenge. Read more and vote here!
Sanofi has narrowed down the field of potential buyers to drug companies from Brazil and India, plus several private equity funds, Reuters reports.
After ushering Juno through early fundraising, an IPO, clinical setbacks and more, CEO Hans Bishop is set for a big payday.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
Reports say that Nestle backed off as leader to buy Merck KGaA’s consumer businesses and that Pfizer has only two interested parties.
Let’s just say it hasn’t been a great week for Novo Nordisk.
Teva woke up with a big hangover after shelling out $40.5 billion for Allergan's generics unit, but now it has a $700 million remedy.
AbbVie may not seem like the kind of company to chase down mammoth deals. But that doesn’t mean it won’t do just that.
Johnson & Johnson has plenty of money coming in from overseas, thanks to U.S. tax reform. But it won’t be spending it on Pfizer’s OTC unit.
Juno Therapeutics CEO Hans Bishop is in line for a nice payday when his company seals the deal with Celgene.
Sanofi finally scored a deal. It plans to shell out $11.6 billion for Bioverativ, the hemophilia-focused drugmaker spun off by Biogen just last year.
Earlier this month, reports said Acorda could be scouting buyers. And now, rumors are swirling as to who those potential bidders might be.